| Title | Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Alter RA, White TG, Fanous AA, Chakraborty S, Filippi CG, Pisapia DJ, Tsiouris AJohn, Boockvar JA |
| Journal | J Exp Ther Oncol |
| Volume | 12 |
| Issue | 1 |
| Pagination | 67-71 |
| Date Published | 2017 May |
| ISSN | 1359-4117 |
| Keywords | Adult, Bevacizumab, Blood-Brain Barrier, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Male, Neoplasm Recurrence, Local, Temozolomide |
| Abstract | OBJECTIVE: Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, following primary resection, received temozolomide. After a second resection, he received one dose of IA bevacizumab with BBBD using mannitol, preventing regrowth for 2.5 years. Following tumor regrowth, the patient received another dose of IA bevacizumab with BBBD, which has prevented regrowth for another year. |
| Alternate Journal | J Exp Ther Oncol |
| PubMed ID | 28472567 |
Related Faculty:
David Pisapia, M.D.